Linerixibat

未知生产厂商

GSK2330672 has been investigated for the treatment of Diabetes Mellitus, Type 2.

医学正文保留数据源原文，避免将未经专业审核的机器翻译呈现为临床事实。

概览

GSK2330672 has been investigated for the treatment of Diabetes Mellitus, Type 2.

Treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC) in adult patients (investigational)

每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。

FORMS OF LINERIXIBAT
EP 4267558 A1申请人: GLAXOSMITHKLINE IP NO 2 LTD优先权: 2020
CN
EP
US
WO
5 件公开
NOVEL USE OF AN ILEAL BILE ACID TRANSPORTER INHIBITOR FOR THE TREATMENT OF PRURITUS
EP 4724071 A1申请人: GLAXOSMITHKLINE IP NO 2 LTD优先权: 2023
EP
WO
2 件公开
SOLID STATE FORMS OF LINERIXIBAT AND PROCESS FOR PREPARATION THEREOF
EP 4791724 A1申请人: ASSIA CHEM IND LTD优先权: 2023
EP
WO
2 件公开